Last reviewed · How we verify
HKT-500 Ketoprofen Topical Patch
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Localized musculoskeletal pain and inflammation, Osteoarthritis pain (topical).
At a glance
| Generic name | HKT-500 Ketoprofen Topical Patch |
|---|---|
| Also known as | Ketoprofen Topical Patch |
| Sponsor | Hisamitsu Pharmaceutical Co., Inc. |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
HKT-500 is a transdermal patch formulation of ketoprofen designed to deliver the NSAID directly through the skin to target localized pain and inflammation. By inhibiting COX-1 and COX-2 enzymes, ketoprofen reduces prostaglandin production, which mediates inflammatory responses and pain signaling. The topical patch formulation aims to minimize systemic exposure and associated gastrointestinal and cardiovascular risks associated with oral NSAIDs.
Approved indications
- Localized musculoskeletal pain and inflammation
- Osteoarthritis pain (topical)
Common side effects
- Skin irritation or dermatitis at application site
- Photosensitivity
- Pruritus
Key clinical trials
- HKT-500-US12 In Adult Patients With OA Knee Pain (PHASE2)
- HKT-500 in the Treatment of Adult Patients With Ankle Sprain (PHASE3)
- HKT-500 in Adult Patients With Shoulder Pain (PHASE3)
- HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain (PHASE3)
- HKT-500 in Adult Patients With Ankle Sprain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HKT-500 Ketoprofen Topical Patch CI brief — competitive landscape report
- HKT-500 Ketoprofen Topical Patch updates RSS · CI watch RSS
- Hisamitsu Pharmaceutical Co., Inc. portfolio CI